I am a healthcare professional in the UK
I am a patient or member of the public
1 minute
EBMT 2025 Congress Highlights
This post‑EBMT 2025 podcast brings together Prof Karl Peggs, Director of NIHR University College London Hospitals Biomedical Research Centre and the Sir Naim Dangoor Centre for Cellular Immunotherapy with hosts Richard Shardlow and Anna Czajka, alongside contributions from Dr Emma Nicholson, Dr Vinay Guntiboiner, Jess Pealing and Nick Duncan. They discuss key take‑aways on advances in myelofibrosis transplant practice, the evolving role of the gut microbiome and CAR‑T, optimisation of CMV prophylaxis and risk‑stratified post‑allograft management, and the potential of transplant‑specific digital tools and apps to support patients in the early post‑transplant period. They also touch on the interplay between GvHD and viral infections such as CMV, late CMV reactivation despite pharmacological prophylaxis, and early experience with patient‑support apps in routine practice
Brightcove Video
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
